PROQUAZONE (BIARSAN) IN THE TREATMENT OF JUVENILE RHEUMATOID-ARTHRITIS - A SEGMENT-I STUDY

  • 1 January 1982
    • journal article
    • research article
    • Vol. 9  (1) , 135-139
Abstract
Patients (33) with JRA [juvenile rheumatoid arthritis] were treated with proquazone during a 4-wk, open-labeled, noncontrolled trial. Doses increased from 400 mg/m2 per day up to 800 mg/m2 per day, not to exceed 960 mg/day. Oral administration was 4 times/day. One patient did not complete the study because an erythematous rash developed. Efficacy analysis showed significant decreases in the total number of active joints, the number and severity of joints with tenderness and limitation of motion, duration of morning stiffness and travel time (in all cases P < 0.05). The drug appears to be similar in efficacy and safety to other nonsteroidal antiinflammatory drugs that have been studied in children.